Skip to main content
. 2020 Mar 20;50(4):442–452. doi: 10.1111/cea.13561

Figure 1.

Figure 1

Indirect treatment comparisons of benralizumab and mepolizumab for (A) percentage reduction in oral corticosteroid (OCS) dosage, (B) percentage of patients with OCS elimination, and (C) reduction in annual rate of clinically significant exacerbations. CI: confidence interval; Q4W: every 4 wk; Q8W: every 8 wk (first three doses every 4 wk)